effects in neurology (2) and BD (3) patients warrant caution. I describe a case of severe suicidal symptoms associated with topiramate in a BD patient.
Case Report
Ms Y, aged 41 years, has a 7-year history of BD. For the first 5 years, she did well on lithium carbonate. However, lithium was discontinued owing to intolerable dermatological conditions. She was taking carbamazepine 400 mg twice daily and levothyroxine 0.15 mg daily (for hypothyroidism) when topiramate was added as an adjuvant mood stabilizer and because of weight gain. The topiramate dosage was gradually increased to 50 mg 3 times daily. A few weeks after she had begun the 150-mg daily dosage of topiramate, Ms Y noticed the onset of sudden and severe suicidal symptoms. She had made her will and started putting her life in order, when her husband suspected a serious problem and brought her to our attention. She was obviously suffering from depression and admitted to planning to take her life. Topiramate was the only medication recently increased, and we were aware of its association with psychiatric symptoms. It was therefore stopped immediately, and Ms Y was closely monitored. Within a week, her mood stabilized: she become euthymic, and her suicidal symptoms cleared completely.
Among obese subjects with BD, the weight loss potential of topiramate may be beneficial and significant (4, 5) . Side effects, such as sedation, nausea, headache, dizziness, and cognitive effects, have been reported in 82% of BD patients taking topiramate, with 36% discontinuing treatment because of side effects (5) . Topiramate has also been associated with development of depressive and psychotic symptoms in patients with epilepsy and BD (2, 6) .
To my knowledge, this is the first report of severe suicidality associated with topiramate use in a patient with BD. Depression and suicidality are common features of mood disorder patients; however, the close temporal relation of newonset suicidal symptoms and the addition of topiramate, together with the speedy resolution after its discontinuation, highlight a possible relation between topiramate and the suicidal behaviour.
Topiramate has some usefulness in the management of psychiatric illness, especially when there is associated obesity. Nevertheless, clinicians should be aware that topiramate may be associated with the development of serious psychiatric symptoms, including severe suicidality, through a poorly understood mechanism that may involve multiple neurotransmitters.
G Abraham, MD, FRCPC Kingston, Ontario

Bright-Light Therapy in Somatization Disorder
Dear Editor:
The core features of somatization disorder are recurrent and multiple physical complaints that are not fully explained by physical factors and that result in medical attention or significant impairment. Somatization disorder (SD) is a chronic but fluctuating disorder that rarely remits completely. It is difficult to treat, and there appears to be no single superior treatment approach (1) . We report a case of SD treated with bright-light therapy.
Case Report
Ms K is a 39-year-old, married woman with a history of depression, SD, and 4 suicide attempts. She reported experiencing somatic complaints and depressive symptoms after she was married. She was treated for 4 years with tioridazine, alprazolam, and mirtazapine, until her last suicide attempt resulted in hospitalization. Her presenting symptoms were irritability, low mood, and frequent crying episodes. Additional somatic complaints were headache, low back pain, and dysmenorrhea. She was diagnosed with major depressive disorder (MDD) and SD according to DSM-IV criteria. Her cardiological, neurosurgical, neurological, gastroenterological, and ophthalmological examinations and routine laboratory examinations, including thyroid hormones, were all normal. She was started on a regimen of venlafaxine 150 mg daily and zopiclone 7.5 mg daily, as needed, for her sleep problems. On the fifteenth day, she continued to complain of somatic symptoms and long durations of sleep latency. Zopiclone was discontinued, and bright-light therapy was started. Light exposure was scheduled in the early morning because of her delayed sleep-wake pattern. We used a light box and an active lighttreatment condition of 10 000-lux white light for 30 minutes (Sadelite, Northern Light Technologies, Montreal, Quebec, Canada). We used the Visual Analog Scale (VAS) to measure her subjective somatic complaints, sleep, and appetite changes. After 2 weeks of light therapy, her Hamilton Depression Rating Scale (HDRS) score fell from 41 to 11. Her multiple subjective somatic complaints showed 80% to 90% improvement, and sleep latency shortened. We found no difference between morning and evening measurements of subjective complaints. She was discharged from the hospital with a regimen of venlafaxine 150 mg daily.
Light therapy quickly reduced the somatic symptoms and augmented the antidepressant therapy success in this patient (2) . The reduction rate of the somatic symptoms was highest for the first 3 days of light therapy. Beyond the antidepressant effects, this case report suggests that light therapy could be useful for treating SD. SD patients with concurrent seasonal affective disorder (SAD) may be most likely to respond to light therapy and bright light, which may act as a strong zeitgeber to synchronize their circadian rhythms.
Okan Caliyurt, MD Edirne, Turkey
Venlafaxine-Induced Delirium
Dear Editor:
Venlafaxine has been associated with delirium but, typically, only in the context of serotonin syndrome. We are aware of only a single report of isolated delirium attributable to venlafaxine (1). Venlafaxine inhibits serotonin and norepinephrine reuptake. It is also a weak inhibitor of dopamine reuptake. Interestingly, venlafaxine has one of the highest incidences of precipitating serotonin syndrome and has even been shown to elicit serotonin syndrome on its own (2, 3) . We report a case of isolated delirium in an individual receiving venlafaxine and ibuprofen.
Case Report
Ms A, aged 46 years, presented to the emergency department disoriented, with auditory hallucinations, loose associations, irritability, and a disorganized thought process. Collateral history revealed that the onset of symptoms developed suddenly, in the previous 36 hours. Her medical history was noncontributory. Her psychiatric history included dysthymia and alcohol dependence, although she claimed to have abstained from alcohol for the past 5 years. She had a long history of ibuprofen consumption (600 mg orally 3 times daily) and felt that this helped her with irritability and reduced her craving for nicotine. Approximately 4 weeks prior to presenting, she was started on venlafaxine 37.5 mg orally each morning and 75 mg orally at bedtime, for depression. She was given a sample of venlafaxine and admitted to taking more than the recommended amount, owing to an unclear understanding of the prescribed dosage.
Other causes of delirium were investigated through examination and laboratory values. Her initial blood pressure was 170/94, with a subsequent recording of 140/79. The rest of her physical and neurological exam was within normal limits. Blood alcohol level was undetected, and other laboratory values, including thyroid-stimulating hormone (TSH), complete blood count (CBC), and a basic metabolic panel, were essentially normal. Regrettably, a serum venlafaxine level was not drawn.
Ms A was admitted to the psychiatric unit and started on venlafaxine (extended release) 150 mg daily and olanzapine 5 mg daily at bedtime. Two days after admission, the patient's delirium resolved and she was discharged on venlafaxine (extended release) 150 mg daily. Discontinuation of ibuprofen was advised. Follow-up 6 weeks later revealed no residual effects of the delirium.
The delirium illustrated in Ms A was most likely produced by high levels of venlafaxine. To our knowledge, there is no literature to support the idea that ibuprofen interacts with venlafaxine; however, it is plausible, considering that both are metabolized by the liver. Whether this patient's delirium was on the continuum of serotonin syndrome, even though she clearly did not demonstrate autonomic instability or neuromuscular changes, remains unresolved. When high levels of venlafaxine are suspected, a high index of suspicion for serotonin syndrome and delirium is warranted. Owing to venlafaxine's increased popularity, we encourage further investigation of the therapeutic index and potential drug interactions of venlafaxine.
